N9289

NVP-231

≥98% (HPLC)

• Sinônimo(s): N-[2-(benzoylamino)-6-benzothiazolyl]-Tricyclo[3.3.1.13,7]decane-1-carboxamide, adamantane-1-carboxylic acid (2-benzoylamino-benzothiazol-6-yl)amide
• Fórmula empírica (Notação de Hill): C₂₅H₂₅N₃O₂S
• Número CAS: 362003-83-6
• Peso molecular: 431.55
• Número MDL: MFCD01988824
• Código UNSPSC: 12352200
• ID de substância PubChem: 329818618
• NACRES: NA.77

Propriedades

• Nível de qualidade: 100
• Ensaio: ≥98% (HPLC)
• forma: powder
• cor: white to off-white
• solubilidade: DMSO: >10 mg/mL
• originador: Novartis
• temperatura de armazenamento: 2-8°C
• cadeia de caracteres SMILES: O=C(Nc1nc2ccc(NC(=O)C34C[C@H]5C[C@H](C[C@H](C5)C3)C4)cc2s1)c6ccccc6
• InChI: 1S/C25H25N3O2S/c29-22(18-4-2-1-3-5-18)28-24-27-20-7-6-19(11-21(20)31-24)26-23(30)25-12-15-8-16(13-25)10-17(9-15)14-25/h1-7,11,15-17H,8-10,12-14H2,(H,26,30)(H,27,28,29)/t15-,16+,17-,25-
• chave InChI: MVSSJPGNLQPWSW-CIRRPZLZSA-N

Descrição

Ações bioquímicas/fisiológicas

Ceramide kinase presents an attractive target for drug development because of its involvement in cell growth and inflammation. CerK biology is still poorly understood thus discovery and availability of inhibitors will facilitate research at this area. NVP-231 is a newly discovered potent, specific and reversible CerK inhibitor that competitively inhibits binding of ceraminde to CerK.

Características e benefícios

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Informações de segurança

• Código de classe de armazenamento: 11 - Combustible Solids
• Classe de risco de água (WGK): nwg
• Ponto de fulgor (°F): Not applicable
• Ponto de fulgor (°C): Not applicable